Differential behavior of diabetic patients compared to non-diabetic on hemodialysis, at the provincial hospital in Camagüey, Cuba
PDF (Español)
PDF

Keywords

hemodialysis
diabetes mellitus
hypertension
liver disease
cardiovascular disease

How to Cite

1.
Benítez Méndez M, Torres DM, Curbelo Rodríguez L, Prieto García F. Differential behavior of diabetic patients compared to non-diabetic on hemodialysis, at the provincial hospital in Camagüey, Cuba. Rev. Colomb. Nefrol. [Internet]. 2017 Aug. 14 [cited 2024 Mar. 29];4(2):168-87. Available from: https://revistanefrologia.org/index.php/rcn/article/view/287

Abstract

Introduction: Currently, Diabetes Mellitus (DM) is considered an epidemic. Patients with
this disease are at high risk of developing diabetic nephropathy. Previous studies have
reported that between 20% and 50% of diagnosed patients are at risk of developing
chronic renal failure which requires hemodialysis treatment or kidney transplant.

Objetives: The aim of this paper is to evaluate the differential behavior of diabetic patients
compared to non-diabetic patients on hemodialysis at University Hospital Manuel Ascunce
Domenech in Camagüey, from August 2009 to January 2014.

Metodology: The descriptive study of cohort of 174 hemodialysis patients (stage 3b, 4 and 5) was performed. A sample of 90 patients, including diabetics and non-diabetics, was studied,
considering inclusion, exclusion, and exit criteria. The survey was the primary source of
information and clinical records of patients on hemodialysis were the secondary source.
Age, sex, comorbidity, time on hemodialysis, nutritional status, type of vascular access,
number of attempts at attaining vascular access, complications resulting from
hemodialysis, and factors impeding the realization of a kidney transplant in diabetic
patients, were the variables studied.

Results: This study indicates that male patients, older than 60 years and with hemodialysis periods less than one year, were predominant. The main comorbidities found were arterial hypertension, ischemic heart disease and liver disease. In diabetic patients, underweight and overweight prevailed.

Conclusions: This research has shown that diabetic patients showed the highest number of dual-lumen catheters and more attempts at attaining vascular access. The main complications that resulted from hemodialysis were hypotension, hypoglycemia and infections. Furthermore, it was found that cardiovascular diseases and advanced age were the factors that prevented the realization of a kidney transplant in diabetic patients.

 

 
https://doi.org/10.22265/acnef.4.2.287
PDF (Español)
PDF

References

Girach A, Manner D, et al. Diabetic microvascular complications: can patientst risk be identified? Areview.Int J ClinPract.2010; 60(11):1471 83.

Villar E, Chang SH, et al. Incidences, treatments, outcomes, and sex effect on survival in patients with end-stage renal disease by diabetes status in Australia and New Zealand (1991 2005). DiabetesCare.2007;30(12):3070-6.

Katherine Carranza, Dolores Veron, Alicia Cercado, Noemi Bautista, Wilson Pozo, Alda Tufro, Delma Veron. Aspectos celulares y moleculares de la nefropatía diabética, rol del VEGF-A. Nefrologia 2015; 35(2):131-138.

Sochett EB, Cherney DZ, et al. Impact of renin angiotensin system modulation on the hyperfiltration state in type 1 diabetes. J Am SocNephrol.2006; 17 (6):1703-9.

Pérez-García R, Martín-Malo A, Fort J, Cuevas X, Lladós F. Baseline characteristics of an incident haemodialysis population in Spain: results from ANSWER a multicentre, prospective, observational cohort study. Nephrol Dial Transplant. 2009; 24:578-88.

Correa Rotter R. Nefropatía diabética. En: Treviño Becerra A. Tratado de nefrología. México, DF: El Prado, 2003; t 1: 663.

Pérez-García R, Martín-Malo A, Fort J, Cuevas X, Lladós F. Baseline characteristics of an incident haemodialysis population in Spain: results from ANSWER –a multicentre, prospective, observational cohort study. Nephrol Dial Transplant.2009;24:570-75.

Carranza K., Verón D., Cercado A., Bautista N., Pozo W., Trufo A., Verñon D. M. Aspectos celulares y moleculares de la nefropatía diabética, rol del VEGF-A. Nefrología 2015; 35(2):131-138

Hossain P, Kawar B, El Nahas M. Obesity and diabetes in the developing world. A growing challenge. N Engl J Med 2007; 356: 213-5.

Tong Z, Yang Z, Patel S Et Al. Promoter polymorphism of the erytropoietin gene in severe diabetic eye and kidney complications. ProcNatlAcadSci USA 2008; 105: 6998-7003.

Sociedad Chilena de Nefrología. Registro de diálisis. XXV. Cuenta de Hemodiálisis Crónica en Chile. Agosto 2005.

Rodríguez Constantín A, Rodríguez Beyrís RP. Insuficiencia renal crónica en pacientes con diabetes mellitus de tipo 2 en un área de salud [artículo en línea].MEDISAN 2009;13(6),

Gu D, Reynolds K, Duan X, Xin X, Chen J, Wu X, et al. Prevalence of diabetes and impaired fasting glucose in the Chinese adult population: International Collaborative Study of Cardiovascular Disease in Asia (InterASIA). Diabetologia. 2008 Sep [citado 15 Jun 2009];46(9):1190-8.

Domínguez E, Seuc A, Aldana D, Licea M, Díaz O, López L. Impacto de la diabetes sobre la duración y calidad de vida de la población cubana: años 1990, 1995, 2000 y 2003. Rev Cubana Endocrinol [serie en Internet]. 2006 Ago [citado 17 Jun 2009]; 17(2).

World health report 2003. Chapter 6: Neglected global epidemics: three growing threats. Geneva: WHO; 2003.

Seuc A, Domínguez E, Díaz O. Esperanza de vida ajustada por diabetes. Rev Cubana Endocrinol. 2003;14: 32-6.

Díaz Díaz O. Importancia de los estudios de mortalidad en diabéticos. Rev Cubana Endocrinol. 2001;12:137-8.

World health report 2003. Chapter 6: Neglected global epidemics: three growing threats. Geneva: WHO; 2003.

Brenner BM, Cooper ME, De Zeew D et al, for the RENAAL Study Group. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2011; 345(12): 861-869.

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes: results of the HOPE study and MICRO-HOPE substudy. Lancet 2010, 355, 253-259.

Wantier JL, Guillausseau RJ. Advanced glycation end products, their receptors and diabeticangiopathy.DiabetesMetab. 2008;29:86-7.

Kalousova M, Zima T, Tesar V, Dusilova-Sulkova S, Skrha J. Advanced glycoxidation end products in chronic diseases-clinical chemistry and genetic background. Mutat Res. 2009;579:37-46.

Setter SM. Biochemical Pathways for microvascular complications of diabetes mellitus. Ann Pharmacother. 2010;37:1858-66.

Zerbini G, Bonfanti R, et al. Persistent renal hypertrophy and faster decline of glomerular filtration rate precede the development of microalbuminuria in type 1 diabetes. Diabetes. 2007 55(9):2620-5.

Ewens KG, George RA, et al. Assessment of 115 candidate genes for diabetic nephropathy by transmission/ disequilibrium test. Diabetes.2005; 54(11):3305-18.

Gerth J, Cohen CD, et al. Collagen type VIII expression in human diabetic nephropathy. Eur J Clin Invest.2007; 37(10):767-73.

Ichinose K, Kawasaki E, et al. Recent advancement of understanding pathogenesis of type 1 diabetes and potential relevance to diabetic nephropathy. Am J Nephrol.2007; 27(6): 554-64.

Remón C, Quirós PL, Portolés R. Consecuencias. y factores relacionados con la remisión tardía en la enfermedad renal crónica. Nefrología. 2009;29(S5):57-61.

Tzamaloukas AH, Friedman EA. Manual de diálisis. In: Daugirdas JT, Blake PG, eds.Diabetes, 2nd ed. Barcelona: Masson, 2003; 472-85.

Hemodialysis Adequacy 2006 Work Group. Clinical Practice Guidelines for Hemodialysis Adequacy. Am J Kidney Dis. 2006;48:3-90.

Tzamaloukas AH, Friedman EA. Manual de diálisis. In: Daugirdas JT, Blake PG, eds. Diabetes, 2nd ed. Barcelona: Masson, 2013; 472-85.

Lassalle M, Labeeuw M, Frimat L, Villar E, Joyeux V, Couchoud C, et al. Age and comorbidity may explain the paradoxical association of an early dialysis start with poor survival. Kidney Int. 2010;77:700-7.

Martínez-Castelao A, Górriz JL, García-López F. Perceived health-related quality of life and comorbidity in diabetic patients starting dialysis (CALVIDIA study).J Nephrol. 2014;17:1-8.

Depner TA. Refi nements and application of urea modeling. In: Depner TA, ed. Prescribing hemodialysis: a guide to urea modelling. Boston: Kluwer, 2011; 167-94.

Konner K. Primary vascular access in diabetic patients: an audit. Nephrol Dial Transplant. 2010;15:1317-25.

Díaz-López M, Plaza-Martínez A, Riera-Vázquez R, Juliá-Montoya J, Manuel-Rimbau E, Corominas-Roura C, et al. Utilidad de las fístulas arteriovenosas autólogas para hemodiálisis en pacientes diabéticos. Angiología. 2002;54:301-7.

Leehey DJ. Hemodialysis in the diabetic patient with end-stage renal disease. Renal Fail. 2014;16:547-53.

Standards of Medical Care in Diabetes 2010. Diabetes Care. 2010;33:4-10.

Drechsler C, Krane V, Ritz E, März W, Wanner C. Glycemic control and cardiovascular events in diabetic hemodialysis patients. Circulation. 2009;120:2421-8.

Lubowsky ND, Siegel R, Pittas AG. Management of glycemia in patients with diabetes mellitus and CKD. Am J Kidney Dis. 2007;50:865-79.

Joy MS, Cefalu WT, Hogan SL, Nachman PH. Long-term glycemic control measurements in diabetic patients receiving hemodialysis. Am J Kidney Dis. 2012;39:297-307.

Kovesdy CP, Park JC, Kalantar-Zadeh K. Glycemic control and burnt-out diabetes in ESRD. Semin Dialysis. 2010;23:148-56.

Lou LM, Gota R, Álvarez R, Gutiérrez Colon JA. Parámetros nutricionales de los pacientes en diabéticos en hemodiálisis. Nefrología. 2010;15:385-6.

Watanabe Y, Yuzawa Y, Mizumoto D, Tamai H, Itoh Y, Kumon S, et al. Long-term followup study of 268 diabetic patients undergoing haemodialysis, with special attention to visual acuity and heterogeneity. Nephrol Dial Transplant. 2013;8:725-34.

Jaar BG, Astor BC, Berns JS, Powe NL. Predictors of amputation and survival following lower extremity revascularization in hemodialysis patients. Kidney Int 2004;65:613-20.

Combe C, Albert JM, Bragg-Gresham JL, Andreucci VE, Disney A, Fukuhara S, et al. The burden of amputation among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2009;54:680-92.

Bernal Pedreño E, Salces Sáez E, Sambruno Giráldez A. Exploración del pie a los pacientes diabéticos en una unidad de hemodiálisis. Rev Soc Esp Enferm Nefrol. 2009;12:111-6.

Jones CA, Krolewski AS, Rogus J, Xue JL, Collins A, Warram JH. Epidemic of end-stage renal disease in people with diabetes in the United States population: do we know the cause? Kidney Int. 2010;67:1684-91.

US Renal Data System. USRDS 2008 Annual Data Report. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2008 (www.usrds.org).

Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2013;30:383-93.

Levin A. Consequences of late referral on patient’s outcomes. Nephrol Dial Transplant. 2010; 15(Suppl 3):8-13.

Foley RN, Murray AM, Li S, Herzog CA, McBean AM, Eggers PW, et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol. 2005;16:489-95.

Meyer KB, Levey AS. Controlling the epidemic of cardiovascular disease in chronic renal disease: report from the National Kidney Foundation Task Force on Cardiovascular Disease. J Am Soc Nephrol. 2008; 9(Suppl):S31-42.

Foley RN, Wang C, Collins AJ. Cardiovascular risk factor profi les and kidney function stage in the US general population: the NHANES III study. Mayo Clin Proc. 2005; 80(10):1270-7.

US Renal Data System. USRDS 2006 Annual Data Report. Atlas of End Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2006. Am J Kidney Dis. 2006;47(Suppl 1):S1.

Locatelli F, Pozzoni P, Del Vecchio L. Renal replacement therapy in patients with diabetes and end-stage renal disease. J Am Soc Nephrol. 2014;15(Suppl 1):S25-9.

Kimmel Pl, Varela MP, Rolf A, Peterson Rl, Weihs KL, Simmens SJ, et al. Interdialytic weight gain and survival in hemodialysis patients: effects of duration of ESRD and diabetes mellitus. Kidney Int. 2010;57:1141-51.

Seliger SL, Weiss NS, Gillen DL, Kestenbaum B, Ball A, Sherrard DJ. HMGCoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int. 2012;61:297-304.

Mason NA, Bailie GR, Satayathum S, Bragg-Gresham JL, Akiba T, Akizawa T, et al. HMG-coenzyme A reductase inhibitor use is associated with mortality reduction in hemodialysis patients. Am J Kidney Dis. 2010;45:119-26.

Wanner C, Krane V, März W, for the German Diabetes and Dialysis Study Group. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2010;353:238-48.

Jaar BG, Coresh J, Plantinga LC. Comparing the risk for death with peritoneal dialysis and hemodialysis in a national cohort of patients with chronic kidney disease. Ann Intern Med. 2010;143:174.

Sutherland DER, Gruessner RWG, Dunn DL, Matas AJ, Humar A, Kandaswamy R, et al. Lessons learned from more than 1000 pancreas transplants at a single institution. Ann Surg. 2011;233:463-501.

Odorico JS, Sollinger HW. Technical and Immunosuppressive advances in transplantation for insulin-dependent diabetes mellitus. World J Surg. 2012;26:194-211.

American Diabetes Association. Pancreas transplantation in type 1 diabetes. Diabetes Care. 2014;27(Suppl 1):105.

Fernández-Balcells M, Esmatjes E, Ricart MJ, Casmitjamna R, Astudillo E. Fernández-Cruz L. Successful pancreas and kidney transplantation: a view of metabolic control. Clin Transplant. 2008;12:582-7.

No national or foreign publication may partially or totally reproduce or translate Revista Colombiana de Nefrología articles or abstracts without prior written permission from the journal’s Editorial Board.

Dimensions


PlumX


Downloads

Download data is not yet available.